Stock ANGN ANGN BIOM
Add to a list
To use this feature you must be a member
Log inSign up

News ANGN BIOM

Equities

ANGN

US03476J1079

Market Closed - Nasdaq
Other stock markets
 01:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
9.1 USD +1.22% Intraday chart for ANGN BIOM +7.02% -9.00%
2023 Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors CI
2023 Angion Biomedia to Implement 10-for-1 Reverse Split MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer
PU
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
AQ
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
AQ
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
AQ
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
AQ
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
AQ
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
AQ
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
AQ
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
AQ
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
AQ
ANGN BIOM : Lymph Node Targeted AMP-peptide Vaccines Generate Functional T cell Immunity Against Mutant p53 and BRAF (SITC – Scientific Poster)
PU
ANGN BIOM : ELI-002 Immunotherapy Induces Broad Polyfunctional T cell Responses in Subjects with High Relapse Risk KRAS Mutated Pancreatic Ductal Adenocarcinoma and Colorectal Cancer (SITC – Scientific Poster)
PU
ANGN BIOM : Management Change - Form 8-K
PU
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
GL
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
GL
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
GL
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GL
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer
GL
Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors
CI
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANGN Stock
  4. News ANGN BIOM